SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced the appointment of Michael L. Eagle as an independent director of the company. Mr. Eagle will also serve as a member of the company's audit committee. This appointment fills the board seat vacated by Scott L. Glenn, who is a co-founder of the company and served on the board of directors since August 2003. The number of company directors remains at nine, with a seven-member independent majority.
